Injected directly into a solid tumour, the OncoLize liquid formulation thickens within seconds to form a soft gel, releasing the loaded drugs safely, at higher concentrations and over a longer period than with the conventional delivery routes of chemo- or immunotherapy.
This localised method of delivery reduces the total drug load required and it is expected to diminish the many side effects associated with conventional delivery of chemo- and immuno-therapies. The company is using the proceeds of the investment to expand the pre-clinical studies and prepare for the first-in-human pancreatic tumour studies.
OncoLize was founded by entrepreneur Mike GW de Leeuw together with Dr Leo de Leede and Prof Helena Kelly with the support of the innovation team in the RCSI Office of Research and Innovation. The production of the drug loaded products will initially take place at RCSI, while in vivo testing and surgical procedures will be carried out by the team of Dr Luuk Hawinkels in the Department of Gastroenterology and Hepatology at the Leiden University Medical Centre.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: IrishTimes - 🏆 3. / 98 Lire la suite »